Lipidsenker- und andere toxische Myopathien

Schöser, Benedikt; Pongratz, D.

doi:10.1007/s00108-005-1490-x

Cited by 13 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary gonadal insufficiency may result from a direct toxic effect of ethanol and acetaldehyde on the gonads with inhibition of the enzymes responsible for the synthesis of sex hormones [39]. Alcohol excess induces acute and/or chronic neuropathy and myopathy [40,41]. Whether such neuropathy can affect erectile function remains to be established.…”

Section: Epidemiologymentioning

confidence: 97%

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Vrentzos¹,

Paraskevas²,

Mikhailidis

2007

CMC

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a common condition with a significant effect on quality of life. The prevalence of ED increases with age and other risk factors (hypertension, diabetes, smoking, coronary heart disease, dyslipidemia and depression). Nitric oxide (NO) activity is adversely affected, in penile and vascular tissue, by these risk factors. Endothelial dysfunction and a reduced generation or bioavailability of NO have emerged as major pathophysiological mechanisms in ED. Hyperlipidemia may impair erectile function by affecting endothelial and smooth muscle cells of the penis. Oxidized low-density lipoprotein is a causative factor for the impaired relaxation response of the corpus cavernosum. Elevated serum cholesterol and reduced high density lipoprotein cholesterol levels are associated with an increased risk of ED. It follows that treating dyslipidemia could have a beneficial effect on ED. Phosphodiesterase type 5 inhibitors are now considered as first line treatment for ED. There is evidence that statins improve responses to these drugs. ED is considered as a warning sign of silent or early vascular disease. The use of statins may be beneficial in these patients.

show abstract

Section: Epidemiologymentioning

confidence: 97%

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Vrentzos¹,

Paraskevas²,

Mikhailidis

2007

CMC

View full text Add to dashboard Cite

show abstract

“…Among these, lipid reducers (statins) and colchicine in particular should be mentioned [ 70 ]. One risk which has been known for a very long time and which occurs with high frequency is the drug-induced myopathy elicited by corticosteroids (steroid-induced myopathy) [ 71 ].…”

Section: Clinical Aspects Of Dysphagiamentioning

confidence: 99%

Position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery and the German Society of Phoniatrics and Pediatric Audiology – Current state of clinical and endoscopic diagnostics, evaluation, and therapy of swallowing disorders in children

Arens

Herrmann

Rohrbach

et al. 2015

GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery; 14:Doc02

View full text Add to dashboard Cite

“…Bisher sind über 4000 Fälle mit einer Lipidsenker-assoziierten Rhabdomyolyse mit 7 akuter Tetraparese, deutlicher CK-Erhöhung (>10fach der Norm), Myoglobinurie, Hyperkaliämie und Koagulopathie. Ein individueller Risiko-Haplotyp (die so genannte SLCO1B1-Variante) scheint hier enorm wichtig zu sein [15,19].…”

Section: Cmeunclassified

Inflammatorische Myopathien

Schöser

2009

Z. Rheumatol.

View full text Add to dashboard Cite

Inflammatory myopathies cover infectious, focal and immunogenic myopathies. This review focuses on the clinical features, diagnostic techniques, pathogenesis and therapy of immunogenic myopathies. Besides myositis associated with other autoimmune disorders, dermatomyositis is the most common immunogenic myopathy. The independent diagnosis of polymyositis has come under debate, since within this group of patients some are now diagnosed as having either hereditary muscular dystrophy with inflammatory signs or inclusion body myositis (IBM). Even more strikingly, patients diagnosed with sporadic IBM may now be diagnosed with either a form of hereditary IBM or with a form belonging to the group of protein aggregate myopathies or myofibrillar myopathies. This re-classification reflects the well-known and clinically evident therapeutic dilemma in many of these patients. Thus the indication for muscle biopsy or rebiopsy requires new consideration and attention.

show abstract

Lipidsenker- und andere toxische Myopathien

Cited by 13 publications

References 29 publications

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery and the German Society of Phoniatrics and Pediatric Audiology – Current state of clinical and endoscopic diagnostics, evaluation, and therapy of swallowing disorders in children

Inflammatorische Myopathien

Contact Info

Product

Resources

About